Is Davunetide FDA approved?

Davunetide is investigational and not FDA approved. It is discussed for research and educational purposes only, not as medical guidance.

Is Noopept FDA approved?

Noopept is not evaluated or approved by the FDA. It is discussed for research and educational purposes only, not as medical guidance.

How is Davunetide administered in research settings?

In research settings, Davunetide is typically administered via the intranasal or subcutaneous routes. PeptideBase does not provide dosing or administration instructions.

How is Noopept administered in research settings?

In research settings, Noopept is typically administered via the oral, sublingual, or intranasal routes. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›Davunetide vs Noopept

Peptide Comparison

Davunetide vs Noopept

Q: What is the difference between Davunetide and Noopept?

Davunetide: Stabilizes microtubules by interacting with tubulin and microtubule-associated proteins. Activates SIRT1, reduces amyloid-β toxicity, and enhances synaptic plasticity. Protects against tau hyperphosphorylation. Noopept: Prodrug converting to cycloprolylglycine; modulates AMPA and NMDA receptors; increases NGF and BDNF expression

Both are Neuro & Cognitive peptides.

Davunetide

NAP

CognitiveInvestigationalResearch Only

No providers listed yet

Full Davunetide profile →

Noopept

N-phenylacetyl-L-prolylglycine ethyl ester

CognitiveNot EvaluatedResearch Only

Half-life: ~15-30 minutes (active metabolite has longer CNS retention)

5 providers listed

Full Noopept profile →

Bottom line

Davunetide carries stronger published evidence (RCT, 3 key studies) than Noopept (Animal, 1); both are research compounds.

Quick Verdict

Davunetide

Half-life

—

Noopept

Half-life

~15-30 minutes (active metabolite has longer CNS retention)

Which One Should You Choose?

Your goal	Better option
Stronger clinical evidence	Davunetide
Further along in FDA review	Davunetide
Oral administration option	Noopept
More provider options (0 vs 5)	Noopept

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

Davunetide

Noopept

Mechanism Family

Neuro & Cognitive

Half-life

—

~15-30 minutes (active metabolite has longer CNS retention)

FDA Status

investigational

not evaluated

Admin Routes

intranasal, subcutaneous

oral, sublingual, intranasal

Availability

Research Only

Providers

None listed

5 listed

Avail. Notes

—

Russian cognitive enhancer (omberacetam). Prescription drug in Russia. NOT FDA-approved. Sold as nootropic supplement in US but does not qualify as dietary supplement under DSHEA. Unscheduled.

Research Evidence

Davunetide

RCT · 3 key studies · most recent 2026

Noopept

Animal · 1 key study · most recent 2022

Research Citations

Davunetide

RCT2013 · Neuropsychopharmacology

Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with sch…

RCT2011 · Schizophrenia Research

Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophren…

Animal2026 · Epilepsy Res

Microtubule-stabilizing drugs suppress convulsions in a C. elegans model of CAMSAP disorders.

Noopept

Animal2022 · Neuroscience Letters

Effect of nootropic dipeptide noopept on CA1 pyramidal neurons involves α7AChRs on interneurons in hippocampa…

About Davunetide

Stabilizes microtubules by interacting with tubulin and microtubule-associated proteins. Activates SIRT1, reduces amyloid-β toxicity, and enhances synaptic plasticity. Protects against tau hyperphosphorylation.

Research Areas

neuroprotectiontau stabilizationcognitive enhancementmemorysynaptic plasticity

About Noopept

Prodrug converting to cycloprolylglycine; modulates AMPA and NMDA receptors; increases NGF and BDNF expression

Research Areas

memory consolidationlearning enhancementneuroprotectionBDNF increase

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

Davunetide

No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.

Noopept

Reported (Unverified — Pending Clinical Review)

severe liver diseaseirritability at high doses

No established clinical contraindications

Find Providers

Where to source these peptides

Providers offering

Davunetide

Browse directory →

Providers offering

Noopept

5 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Neuro & Cognitive Comparisons

Browse all peptides →

Educational research tools — not medical advice.